240 related articles for article (PubMed ID: 27123175)
1. Reimbursement of licensed cell and gene therapies across the major European healthcare markets.
Jørgensen J; Kefalas P
J Mark Access Health Policy; 2015; 3():. PubMed ID: 27123175
[TBL] [Abstract][Full Text] [Related]
2. Market access pathways for cell therapies in France.
Rémuzat C; Toumi M; Jørgensen J; Kefalas P
J Mark Access Health Policy; 2015; 3():. PubMed ID: 27123176
[TBL] [Abstract][Full Text] [Related]
3. Price and reimbursement of advanced therapeutic medicinal products in Europe: are assessment and appraisal diverging from expert recommendations?
Ronco V; Dilecce M; Lanati E; Canonico PL; Jommi C
J Pharm Policy Pract; 2021 Mar; 14(1):30. PubMed ID: 33741076
[TBL] [Abstract][Full Text] [Related]
4. Financing and Reimbursement of Approved Advanced Therapies in Several European Countries.
Iglesias-López C; Agustí A; Vallano A; Obach M
Value Health; 2023 Jun; 26(6):841-853. PubMed ID: 36646280
[TBL] [Abstract][Full Text] [Related]
5. Payer Perspectives on Patient-Reported Outcomes in Health Care Decision Making: Oncology Examples.
Brogan AP; DeMuro C; Barrett AM; D'Alessio D; Bal V; Hogue SL
J Manag Care Spec Pharm; 2017 Feb; 23(2):125-134. PubMed ID: 28125369
[TBL] [Abstract][Full Text] [Related]
6. Pricing and reimbursement mechanisms for advanced therapy medicinal products in 20 countries.
Rejon-Parrilla JC; Espin J; Garner S; Kniazkov S; Epstein D
Front Pharmacol; 2023; 14():1199500. PubMed ID: 38089054
[No Abstract] [Full Text] [Related]
7. Key Considerations in the Health Technology Assessment of Advanced Therapy Medicinal Products in Scotland, The Netherlands, and England.
Ten Ham RMT; Frederix GWJ; Wu O; Goettsch W; Leufkens HGM; Klungel OH; Hoekman J
Value Health; 2022 Mar; 25(3):390-399. PubMed ID: 35227451
[TBL] [Abstract][Full Text] [Related]
8. [Risk sharing methods in middle income countries].
Inotai A; Kaló Z
Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
[TBL] [Abstract][Full Text] [Related]
9. Reinforcing Collaboration and Harmonization to Unlock the Potentials of Advanced Therapy Medical Products: Future Efforts Are Awaited From Manufacturers and Decision-Makers.
Qiu T; Liang S; Wang Y; Dussart C; Borissov B; Toumi M
Front Public Health; 2021; 9():754482. PubMed ID: 34900902
[TBL] [Abstract][Full Text] [Related]
10. Value-based pricing for advanced therapy medicinal products: emerging affordability solutions.
Gonçalves E
Eur J Health Econ; 2022 Mar; 23(2):155-163. PubMed ID: 34106364
[TBL] [Abstract][Full Text] [Related]
11. Advanced therapy medicinal products: current and future perspectives.
Hanna E; Rémuzat C; Auquier P; Toumi M
J Mark Access Health Policy; 2016; 4():. PubMed ID: 27123193
[TBL] [Abstract][Full Text] [Related]
12. Diabetes device reimbursement in the EU-5.
Schäfer E; Schnell G; Bobáková T
J Diabetes Sci Technol; 2013 Jul; 7(4):1084-92. PubMed ID: 23911192
[TBL] [Abstract][Full Text] [Related]
13. Advanced therapy medicinal products and health technology assessment principles and practices for value-based and sustainable healthcare.
Jönsson B; Hampson G; Michaels J; Towse A; von der Schulenburg JG; Wong O
Eur J Health Econ; 2019 Apr; 20(3):427-438. PubMed ID: 30229376
[TBL] [Abstract][Full Text] [Related]
14. Self-monitoring of blood glucose (SMBG) in patients with type 2 diabetes on oral anti-diabetes drugs: cost-effectiveness in France, Germany, Italy, and Spain.
Tunis SL; Willis WD; Foos V
Curr Med Res Opin; 2010 Jan; 26(1):163-75. PubMed ID: 19919377
[TBL] [Abstract][Full Text] [Related]
15. Health Technology Assessment of Advanced Therapy Medicinal Products: Comparison Among 3 European Countries.
Gozzo L; Romano GL; Romano F; Brancati S; Longo L; Vitale DC; Drago F
Front Pharmacol; 2021; 12():755052. PubMed ID: 34690785
[TBL] [Abstract][Full Text] [Related]
16. Outcomes-based reimbursement for gene therapies in practice: the experience of recently launched CAR-T cell therapies in major European countries.
Jørgensen J; Hanna E; Kefalas P
J Mark Access Health Policy; 2020; 8(1):1715536. PubMed ID: 32082514
[No Abstract] [Full Text] [Related]
17. Advanced therapy medicinal products: value judgement and ethical evaluation in health technology assessment.
Gonçalves E
Eur J Health Econ; 2020 Apr; 21(3):311-320. PubMed ID: 31919703
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]